X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (974) 974
Publication (97) 97
Book Review (36) 36
Newspaper Article (21) 21
Newsletter (17) 17
Book Chapter (6) 6
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (705) 705
humans (692) 692
abiraterone acetate (654) 654
prostate cancer (624) 624
male (617) 617
oncology (468) 468
chemotherapy (352) 352
metastasis (327) 327
docetaxel (320) 320
double-blind (293) 293
cancer (283) 283
prostatic neoplasms, castration-resistant - drug therapy (283) 283
care and treatment (276) 276
enzalutamide (246) 246
urology & nephrology (236) 236
aged (206) 206
increased survival (206) 206
treatment outcome (200) 200
middle aged (190) 190
prostatic neoplasms, castration-resistant - pathology (189) 189
antineoplastic agents - therapeutic use (187) 187
antitumor-activity (182) 182
prednisone (176) 176
survival (176) 176
prostatic neoplasms - drug therapy (169) 169
mitoxantrone plus prednisone (167) 167
castration (159) 159
plus prednisone (157) 157
abiraterone (153) 153
men (153) 153
androgens (147) 147
castration-resistant prostate cancer (141) 141
research (140) 140
survival analysis (136) 136
therapy (125) 125
aged, 80 and over (123) 123
androgen antagonists - therapeutic use (120) 120
androgen receptor (120) 120
drug therapy (120) 120
medicine & public health (113) 113
antineoplastic combined chemotherapy protocols - therapeutic use (112) 112
neoplasm metastasis (112) 112
cancer therapies (110) 110
pharmacology & pharmacy (110) 110
corticosteroids (107) 107
patients (107) 107
prostatic neoplasms - pathology (107) 107
clinical trials (106) 106
taxoids - therapeutic use (106) 106
mitoxantrone (105) 105
phenylthiohydantoin - analogs & derivatives (103) 103
prostate (103) 103
analysis (101) 101
cabazitaxel (101) 101
disease-free survival (99) 99
metastases (96) 96
immunotherapy (95) 95
sipuleucel-t (93) 93
urology (90) 90
health aspects (88) 88
orchiectomy (88) 88
development and progression (87) 87
disease progression (85) 85
open-label (85) 85
acetates (84) 84
adult (83) 83
metastatic castration-resistant prostate cancer (83) 83
androgen-deprivation therapy (81) 81
animals (78) 78
cyp17 (76) 76
retrospective studies (76) 76
female (74) 74
i clinical-trial (74) 74
quality-of-life (74) 74
antineoplastic agents, hormonal - therapeutic use (73) 73
phase-iii trial (73) 73
prognosis (73) 73
phenylthiohydantoin - therapeutic use (72) 72
quality of life (72) 72
review (72) 72
acetate (70) 70
phase-ii (69) 69
placebo-controlled phase-3 (69) 69
hematology, oncology and palliative medicine (67) 67
abiraterone acetate - therapeutic use (66) 66
clinical trials as topic (63) 63
testosterone (63) 63
prostate-specific antigen - blood (62) 62
prostatic neoplasms - therapy (62) 62
prostatic neoplasms, castration-resistant - mortality (62) 62
trial (60) 60
article (58) 58
acetate plus prednisone (57) 57
clinical-trials (56) 56
prednisone - administration & dosage (56) 56
bone neoplasms - secondary (55) 55
drug resistance, neoplasm (55) 55
prostate-specific antigen (55) 55
abiraterone acetate - administration & dosage (54) 54
patient outcomes (54) 54
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Androgen Antagonists - therapeutic use | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 7, pp. 723 - 731
Journal Article
Lancet Oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1193 - 1199
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 194 - 206
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 338 - 348
Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | ONCOLOGY | MEN | END-POINTS | ABIRATERONE ACETATE | INCREASED SURVIVAL | DOCETAXEL | ENZALUTAMIDE | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | North America | Prostatic Neoplasms, Castration-Resistant - pathology | Time Factors | Prednisone - administration & dosage | Double-Blind Method | Europe | Risk Factors | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Adenocarcinoma - secondary | Disease Progression | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Naphthalenes - administration & dosage | Intention to Treat Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Australia | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Cytochrome P-450 | Clinical trials | Prednisone | Metastasis | Prostate cancer | Cancer | Steroids
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 22, pp. 6812 - 6822
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2018, Volume 119, Issue 9, pp. 1052 - 1059
Journal Article
Journal Article
Journal Article
Journal Article